ClinicalTrials.gg
RecruitingNCT06295822Updated Apr 10, 2024

The Effectiveness of Chinese Medicine Nuan-gong-ye on Primary Dysmenorrhea

An interventional study of Nuan-gong-ye and Placebo in Chinese Medicine and Primary Dysmenorrhea, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-10.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Dysmenorrhea with a site in Taiwan — 4 open to participants now, 6 under way, none of them phase 3. Dysmenorrhea · Taiwan.

Planned enrollment
5th of 15
82 · median 60
Started
2024
with 1 other
No phase
12 of 15
3 open now
Registered
10th of 15
by date
Lead sponsor
3 of 15
China Medical University Hospital

Among the 15 studies in Dysmenorrhea with a site in Taiwan, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 12 with no phase, and was the 10th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

4 of the 15 studies in Dysmenorrhea with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Dysmenorrhea with a site in Taiwan, or all of them as a file.
02

Study summary

Primary dysmenorrhea is a common under-diagnosed complaint, with a prevalence of about 45-95% in women of childbearing age and about 10-25% in severe cases. Menstrual pain can be classified as primary or secondary. Primary menstrual pain is a crampy pain in the lower abdomen without any pelvic pathology, which usually occurs 6 to 12 months after the first menstruation. Primary menstrual pain is usually most severe on the first day of the menstrual cycle and lasts for 8 to 72 hours. The cause is still unknown, but studies suggest that it may be related to increased prostaglandins, which cause painful contractions of the uterus. The pain is often accompanied by other menstrual discomfort symptoms, including headache, breast tenderness, drowsiness, nausea, vomiting, constipation or diarrhea, and psychological anxiety, depression or irritability. In the case of secondary menstrual pain, there are clear pelvic pathologies, such as endometriosis, uterine fibroids, and pelvic inflammatory disease.

Read the detailed description

In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400, while the placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400, all from the same batch. A bottle of nuan-gong-ye will be taken for HPLC fingerprint to examine its components. A total of 140 people will be divided randomly into two groups, of which the experimental group using nuan-gong-ye and the control group using a placebo. Four menstrual cycles of the clinical trial will be conducted after recruitment. The first menstrual cycle will be non-interventional, with subjects filling out Basic information sheet, Visual Analogue Scale (VAS), and Short Form McGill Pain Questionnaire (MPQ-SF). In the second to fourth menstrual cycles, two bottles of approximately 16 ml of nuan-gong-ye will be applied. During these three cycles, the application will begin five days before each menstrual period and end on the third day of the menstruation, with the VAS, McGill scale, and side effects questionnaire being completed. The skin should be dry before application. For each application of nuan-gong-ye or placebo, apply 10 circles clockwise from the navel to a circular area with a radius of 8 to 13 cm. The first application will be done after waking up, the second and third apply every five hours, and the fourth apply at bedtime, for a total of four applications a day. Other relief measures such as Chinese medicine, hot compresses, abdominal massage, acupuncture, and the use of other essential oils are prohibited during the research period, while painkillers are not.

03

Conditions studied

  • Chinese Medicine
  • Primary Dysmenorrhea

Browse trials for

Keywords

  • Chinese Medicine
  • Nuan-gong-ye
  • Primary dysmenorrhea
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20-40 year-old women
  • Regular menstrual cycle of 21-35 days, with menstruation lasting 3-7 days
  • Dysmenorrhea started before the age of 20, and have menstrual pain every month
  • No organic lesions on ultrasound within one year (either abdomen or vagina)
  • VAS score above 4
  • Agree to participate in the study and sign the consent form

Exclusion criteria

Exclusion Criteria:

  • Has used the same formula of Nuan-gong-ye before.
  • Allergic to Nuan-gong-ye.
  • Has abdominal wounds, infections, or skin diseases.
  • Pregnant or planning to become pregnant within the next five months.
  • Has taken traditional Chinese medicine or prescribed medication for menstrual pain by a Chinese medicine doctor in the past month.
  • Has major illnesses defined by the Taiwan National Health Insurance Administration, such as cancer, heart disease, etc.
  • Has mental illness or cognitive impairment and cannot independently fill out the questionnaire.
  • Has a history of epilepsy or pelvic disorders.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Nuan-gong-ye

    Drug: Nuan-gong-ye

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugNuan-gong-ye

    In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.

  • OtherPlacebo

    The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS)

    The intensity of menstrual pain was measured by the Visual Analogue Scale (VAS). The VAS scale is a continuous horizontal line ten centimeters in length. The left end of the line, marked as 0, represents 'no pain,' while the right end, marked as 10, represents 'the most intense pain'. The VAS and McGill scales were used to assess the difference before and after each menstrual cycle.

    Time frame: 4 months

Secondary outcomes

  1. Short Form McGill Pain Questionnaire (MPQ-SF)

    Pain perception was measured by the Short Form McGill Pain Questionnaire (MPQ-SF). The scale consists of 15 items, with scores ranging from 0 to 3 to assess the intensity of each pain. 0 represents 'none,' 1 represents 'mild pain,' 2 represents 'moderate pain,' and 3 represents 'severe pain.' The VAS and McGill scales were used to assess the difference before and after each menstrual cycle.

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Aug 2025, 17 months after the start.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 17 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Mar 6, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Aug 31, 2025
CompletionEst.
Feb 28, 2026
Last update
Apr 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06295822
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Mar 4, 2024
Primary completion
Aug 31, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Apr 10, 2024

Study contacts

HSUAN HSUAN WU
Contact
whh900710@gmail.com
+886928030693

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion